Jose A Obeso
Jose A Obeso
HM CINAC (Centro Integral de Neurociencias), Madrid, Spain
Verified email at
Cited by
Cited by
MDS clinical diagnostic criteria for Parkinson's disease
RB Postuma, D Berg, M Stern, W Poewe, CW Olanow, W Oertel, J Obeso, ...
Movement disorders 30 (12), 1591-1601, 2015
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up
MC Rodriguez-Oroz, JA Obeso, AE Lang, JL Houeto, P Pollak, ...
Brain 128 (10), 2240-2249, 2005
Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease
Deep-Brain Stimulation for Parkinson's Disease Study Group
New England Journal of Medicine 345 (13), 956-963, 2001
Manual motor performance in a deafferented man
JC Rothwell, MM Traub, BL Day, JA Obeso, PK Thomas, CD Marsden
Brain 105 (3), 515-542, 1982
Pathophysiology of the basal ganglia in Parkinson's disease
JA Obeso, MC Rodriguez-Oroz, M Rodriguez, JL Lanciego, J Artieda, ...
Trends in neurosciences 23, S8-S19, 2000
The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease
CD Marsden, JA Obeso
Brain 117 (4), 877-897, 1994
Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease
P Redgrave, M Rodriguez, Y Smith, MC Rodriguez-Oroz, S Lehericy, ...
Nature Reviews Neuroscience 11 (11), 760-772, 2010
Missing pieces in the Parkinson's disease puzzle
JA Obeso, MC Rodriguez-Oroz, CG Goetz, C Marin, JH Kordower, ...
Nature medicine 16 (6), 653-661, 2010
Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms
MC Rodriguez-Oroz, M Jahanshahi, P Krack, I Litvan, R Macias, E Bezard, ...
The Lancet Neurology 8 (12), 1128-1139, 2009
MDS research criteria for prodromal Parkinson's disease
D Berg, RB Postuma, CH Adler, BR Bloem, P Chan, B Dubois, T Gasser, ...
Movement Disorders 30 (12), 1600-1611, 2015
The anatomical basis of symptomatic hemidystonia
CD Marsden, JA Obeso, JJ Zarranz, AE Lang
Brain 108 (2), 463-483, 1985
Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease
JA Obeso, MC Rodríguez‐Oroz, B Benitez‐Temino, FJ Blesa, J Guridi, ...
Movement disorders: official journal of the Movement Disorder Society 23 (S3 …, 2008
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
CW Olanow, JA Obeso, F Stocchi
The Lancet Neurology 5 (8), 677-687, 2006
Levodopa motor complications in Parkinson's disease
JA Obeso, CW Olanow, JG Nutt
Trends in neurosciences 23, S2-S7, 2000
The impact of deep brain stimulation on executive function in Parkinson's disease
M Jahanshahi, CMA Ardouin, RG Brown, JC Rothwell, J Obeso, ...
Brain 123 (6), 1142-1154, 2000
The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics
MC Rodriguez-Oroz, M Rodriguez, J Guridi, K Mewes, V Chockkman, ...
Brain 124 (9), 1777-1790, 2001
Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys
A Recasens, B Dehay, J Bové, I Carballo‐Carbajal, S Dovero, ...
Annals of neurology 75 (3), 351-362, 2014
Subthalamic nucleus‐mediated excitotoxicity in Parkinson's disease: a target for neuroprotection
MC Rodriguez, JA Obeso, CW Olanow
Annals of neurology 44 (S1 1), S175-S188, 1998
Selective neuronal vulnerability in Parkinson disease
DJ Surmeier, JA Obeso, GM Halliday
Nature Reviews Neuroscience 18 (2), 101, 2017
Levodopa in the treatment of Parkinson's disease: current controversies
CW Olanow, Y Agid, Y Mizuno, A Albanese, U Bonucelli, P Damier, ...
Movement disorders 19 (9), 997-1005, 2004
The system can't perform the operation now. Try again later.
Articles 1–20